Use the following information to answer the next few questions. CML (chronic myelogenous leukemia) results from a translocation between human chromosomes 9 and 22. The resulting chromosome 22 is significantly shorter than usual, and it is known as a Philadelphia (Ph') chromosome. The junction at the site of the translocation causes overexpression of a thymine kinase receptor. A new drug (Gleevec or imatinib) has been found to inhibit the disease if the patient is treated early. -Why would Gleevec most probably cause remission of the disease?
A) It reverses the chromosomal translocation. B) It eliminates the Ph' chromosome. C) It removes Ph'-containing progenitor cells. D) The drug inhibits the replication of the affected chromosome. E) The drug inhibits the specific thymine kinase receptor.